Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, Tedesco M, Zupi G, Mottolese M
Pathology Department, Regina Elena Cancer Institute, Rome, Italy.
Int J Cancer. 1999 Dec 22;84(6):545-52. doi: 10.1002/(sici)1097-0215(19991222)84:6<545::aid-ijc1>3.0.co;2-2.
About 40% of patients with colorectal carcinoma will develop local or distant tumour recurrences. Integrated analyses of bio-pathological markers, predictive of tumour aggressiveness, may offer a more rational approach to planning adjuvant therapy. To this end, we analysed the correlation between p53 accumulation, Bcl-2 expression, DNA ploidy, cell proliferation and conventional clinico-pathological parameters by testing the prognostic significance of these variables in a series of 171 colorectal carcinoma patients with long-term follow-up. The relationships among the various bio-pathological parameters, analysed by multiple correspondence analysis, showed 2 different clinico-biological profiles. The first, characterised by p53 negativity, Bcl-2 positivity, diploidy, low percentage of cells in S-phase (%S-phase), a low Ki-67 score, is associated with Dukes' A-B stage, well differentiated tumours and lack of relapse. The second, defined by p53 positivity, Bcl-2 negativity, aneuploidy, high %S-phase and elevated Ki-67 score, correlates with Dukes' C-D stage, poorly differentiated tumours and presence of relapse. When these parameters were examined according to Kaplan-Meier's method, significantly shorter disease-free (DFS) and overall survival (OS) were also observed in patients bearing p53 positive and Bcl-2 negative tumours, in Dukes' B stage. In multivariate analysis, p53 accumulation and Bcl-2 expression emerged as independent predictors of a worse and better clinical outcome, respectively. Our results indicate that, in colorectal adenocarcinomas, a biological profile, based on the combined evaluation of p53 and Bcl-2, may be useful for identifying high risk patients to be enrolled in an adjuvant setting, mainly in an early stage of the disease. Int. J. Cancer (Pred. Oncol.) 84:545-552, 1999.
约40%的结直肠癌患者会出现局部或远处肿瘤复发。对预测肿瘤侵袭性的生物病理标志物进行综合分析,可能为辅助治疗方案的制定提供更合理的方法。为此,我们通过检测171例接受长期随访的结直肠癌患者中这些变量的预后意义,分析了p53蓄积、Bcl-2表达、DNA倍体、细胞增殖与传统临床病理参数之间的相关性。通过多重对应分析对各种生物病理参数之间的关系进行分析,显示出两种不同的临床生物学特征。第一种特征为p53阴性、Bcl-2阳性、二倍体、S期细胞百分比低(%S期)、Ki-67评分低,与Dukes' A - B期、高分化肿瘤及无复发相关。第二种特征为p53阳性、Bcl-2阴性、非整倍体、高%S期及Ki-67评分升高,与Dukes' C - D期、低分化肿瘤及复发相关。当根据Kaplan-Meier法检查这些参数时,在Dukes' B期p53阳性和Bcl-2阴性肿瘤患者中也观察到无病生存期(DFS)和总生存期(OS)显著缩短。在多变量分析中,p53蓄积和Bcl-2表达分别成为临床结局较差和较好的独立预测因素。我们的结果表明,在结直肠腺癌中,基于p53和Bcl-2联合评估的生物学特征可能有助于识别需要纳入辅助治疗的高危患者,主要是在疾病的早期阶段。《国际癌症杂志(预测肿瘤学)》84:545 - 552,1999年。